HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity Total deal value of up to $2.3 billion, including upfront, milestone payments and tiered royalties based on net sales SEOUL, South...
Hence then, the article about hanmi pharm signs exclusive licensing deal with genentech for novel obesity therapy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy )
Also on site :
- LIVE: Watch friends and family cross the 2026 Chicago Marathon finish line
- In the 1940s, Howard Hughes bought the peak next to the Hollywood Sign to build a house for Ginger Rogers; in 2010 more than 100 acres of it became part of Griffith Park
- Gardeners Say You Can Still Plant These 8 Vegetables in November—With the Right Conditions for a Future Harvest